Send the following on WhatsApp
Continue to Chathttps://www.marketscreener.com/quote/stock/BIOSENIC-SA-20757385/news/Bone-Therapeutics-Allogeneic-Cell-Therapy-Product-ALLOB-Shows-90-Fusion-Rate-at-24-Months-in-Phas-33668535/?utm_source=whatsapp&utm_medium=social&utm_campaign=share